학술논문

Noninvasive Testing and Surrogate Markers in Invasive Fungal Diseases
Document Type
article
Source
Open Forum Infectious Diseases. 9(6)
Subject
Biomedical and Clinical Sciences
Clinical Sciences
Clinical Research
Clinical Trials and Supportive Activities
Emerging Infectious Diseases
Prevention
Infectious Diseases
4.1 Discovery and preclinical testing of markers and technologies
Detection
screening and diagnosis
Infection
Good Health and Well Being
diagnosis
fungal infections
mycology
Clinical sciences
Medical microbiology
Language
Abstract
Invasive fungal infections continue to increase as at-risk populations expand. The high associated morbidity and mortality with fungal diseases mandate the continued investigation of novel antifungal agents and diagnostic strategies that include surrogate biomarkers. Biologic markers of disease are useful prognostic indicators during clinical care, and their use in place of traditional survival end points may allow for more rapid conduct of clinical trials requiring fewer participants, decreased trial expense, and limited need for long-term follow-up. A number of fungal biomarkers have been developed and extensively evaluated in prospective clinical trials and small series. We examine the evidence for these surrogate biomarkers in this review and provide recommendations for clinicians and regulatory authorities.